Amikacin liposomal nebuliser dispersion is accepted for use within NHS Scotland for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium avium Complex in adults.

Adding dupilumab to standard asthma treatment is more effective than placebo plus standard treatment at reducing the frequency of severe exacerbations, and the use of oral corticosteroids in people with severe asthma with type 2 inflammation, says NICE final draft guidance.

Amikacin liposomal is recommended in NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis.

NICE has issued a partial guideline update after reviewing the evidence on oxygen saturation thresholds for referral to hospital, admission, management and discharge. Quickly find out what's new with this summary.

NICE has issued draft guidance which does not recommend nintedanib for treating progressive fibrosing interstitial lung diseases, excluding idiopathic pulmonary fibrosis.

The treatments recommended are for chronic fibrosing interstitial lung diseases, mycosis fungoides and Sézary syndrome, and metastatic gastric cancer.

Indacaterol acetate/glycopyrronium bromide/mometasone furoate is recommended for the maintenance treatment of asthma in adults.